MCID: NVS001
MIFTS: 49

Neovascular Glaucoma

Categories: Eye diseases, Fetal diseases, Rare diseases

Aliases & Classifications for Neovascular Glaucoma

MalaCards integrated aliases for Neovascular Glaucoma:

Name: Neovascular Glaucoma 12 59 15
Glaucoma, Neovascular 44 73
Secondary Angle-Closure Glaucoma with Rubeosis 12
Glaucoma Neovascular 55

Characteristics:

Orphanet epidemiological data:

59
neovascular glaucoma
Prevalence: 1-5/10000 (Europe);

Classifications:



External Ids:

Disease Ontology 12 DOID:1687
MeSH 44 D015355
Orphanet 59 ORPHA94058
MESH via Orphanet 45 D015355
UMLS via Orphanet 74 C0017609
UMLS 73 C0017609

Summaries for Neovascular Glaucoma

MalaCards based summary : Neovascular Glaucoma, also known as glaucoma, neovascular, is related to microvascular complications of diabetes 5 and microvascular complications of diabetes 1. An important gene associated with Neovascular Glaucoma is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are MAPK signaling pathway and Endochondral Ossification. The drugs Ranibizumab and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and testes, and related phenotypes are photophobia and retinal detachment

Related Diseases for Neovascular Glaucoma

Diseases related to Neovascular Glaucoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 5 30.7 PGF VEGFA
2 microvascular complications of diabetes 1 30.4 TGFB2 VEGFA
3 coats disease 30.3 RS1 VEGFA
4 retinal detachment 30.3 RS1 VEGFA
5 arteries, anomalies of 30.1 PGF VEGFA
6 endophthalmitis 29.7 OPTN VEGFA
7 glaucoma, primary open angle 29.4 OPTN SLC6A13 TGFB2
8 retinoschisis 1, x-linked, juvenile 11.5
9 retinal vein occlusion 10.4
10 melanoma 10.4
11 central retinal vein occlusion 10.4
12 microvascular complications of diabetes 2 10.4
13 rubeosis iridis 10.4
14 cataract 10.2
15 diabetes mellitus 10.2
16 retinal artery occlusion 10.2
17 preretinal fibrosis 10.1 TGFB2 VEGFA
18 melanoma, uveal 10.1
19 ischemia 10.1
20 vitreous disease 10.1 TGFB2 VEGFA
21 macular holes 10.1 TGFB2 VEGFA
22 kuhnt-junius degeneration 10.1 PGF VEGFA
23 epithelioid hemangioendothelioma 10.1 PGF VEGFA
24 cancer-associated retinopathy 10.1 PGF VEGFA
25 retinal vascular occlusion 10.1 PGF VEGFA
26 neurofibromatosis, type i 10.1
27 central retinal artery occlusion 10.1
28 uveitis 10.1
29 carotid artery disease 10.1
30 limb ischemia 10.1 PGF VEGFA
31 ectopic pregnancy 10.1 PGF VEGFA
32 placental insufficiency 10.1 PGF VEGFA
33 retinal vascular disease 10.1 PGF VEGFA
34 severe pre-eclampsia 10.0 PGF VEGFA
35 rosacea 10.0 IER3IP1 VEGFA
36 retinal ischemia 10.0
37 neuroretinitis 10.0
38 open-angle glaucoma 10.0
39 retinal vasculitis 10.0
40 sympathetic ophthalmia 10.0
41 branch retinal artery occlusion 10.0
42 optic nerve glioma 10.0
43 carotid artery occlusion 10.0
44 vasculitis 10.0
45 glioma 10.0
46 blood group, globoside system 10.0 OPTN VEGFA
47 chronic closed-angle glaucoma 10.0 OPTN TGFB2
48 central nervous system cancer 10.0 IER3IP1 VEGFA
49 purulent endophthalmitis 10.0 OPTN VEGFA
50 yemenite deaf-blind hypopigmentation syndrome 10.0 OPTN VEGFA

Graphical network of the top 20 diseases related to Neovascular Glaucoma:



Diseases related to Neovascular Glaucoma

Symptoms & Phenotypes for Neovascular Glaucoma

Human phenotypes related to Neovascular Glaucoma:

59 32 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 photophobia 59 32 frequent (33%) Frequent (79-30%) HP:0000613
2 retinal detachment 59 32 very rare (1%) Very rare (<4-1%) HP:0000541
3 visual loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0000572
4 retinal vascular proliferation 59 32 occasional (7.5%) Occasional (29-5%) HP:0007850
5 ocular pain 59 32 frequent (33%) Frequent (79-30%) HP:0200026
6 visual acuity test abnormality 59 32 frequent (33%) Frequent (79-30%) HP:0030532
7 abnormality of the optic nerve 59 32 frequent (33%) Frequent (79-30%) HP:0000587
8 corneal stromal edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0012040
9 increased intraocular pressure 59 32 frequent (33%) Frequent (79-30%) HP:0007906
10 iris neovascularization 59 32 hallmark (90%) Very frequent (99-80%) HP:0011497
11 retinal vein occlusion 59 32 hallmark (90%) Very frequent (99-80%) HP:0012636
12 abnormality of central retinal artery 59 32 frequent (33%) Frequent (79-30%) HP:3000032
13 glaucoma 59 Obligate (100%)
14 abnormality of the anterior chamber 59 Occasional (29-5%)
15 abnormality of the posterior segment of the globe 59 Occasional (29-5%)
16 abnormality of the uvea 59 Frequent (79-30%)
17 abnormal anterior chamber morphology 32 occasional (7.5%) HP:0000593

Drugs & Therapeutics for Neovascular Glaucoma

Drugs for Neovascular Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 347396-82-1 459903
2
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
3
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
4 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
8 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Not Applicable
9 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
10 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Not Applicable
11 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Not Applicable
12 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
13 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Not Applicable
14 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
15 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
16 Endothelial Growth Factors Phase 4,Phase 3,Phase 1,Phase 2
17 Mitomycins Phase 4,Phase 3,Phase 2,Not Applicable
18 Mitogens Phase 4,Phase 3,Phase 2,Phase 1
19 Alkylating Agents Phase 3,Phase 2
20 Anti-Bacterial Agents Phase 3,Phase 2
21 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
22 Antibiotics, Antitubercular Phase 3,Phase 2
23 Pharmaceutical Solutions Phase 2, Phase 3,Phase 1
24 Insulin, Globin Zinc Phase 2, Phase 3
25 insulin Phase 2, Phase 3
26 Anesthetics Phase 2
27
Racepinephrine Approved Not Applicable 329-65-7 838
28
Epinephrine Approved, Vet_approved Not Applicable 51-43-4 5816
29
Pilocarpine Approved, Investigational Not Applicable 54-71-7, 92-13-7 5910
30 Epinephryl borate Not Applicable
31 Peripheral Nervous System Agents Not Applicable
32 Cholinergic Agents Not Applicable
33 Neurotransmitter Agents Not Applicable
34 Autonomic Agents Not Applicable
35 Muscarinic Agonists Not Applicable

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
2 Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma Completed NCT01922154 Phase 4 intravitreal ranibizumab
3 Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma Completed NCT02647515 Phase 4 ranibizumab
4 Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Completed NCT00557232 Phase 4 bevacizumab
5 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
6 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
7 Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study Unknown status NCT02914626 Phase 3 Intravitreal ranibizumab
8 Evaluation of Efficacy and Safety of Susanna Implant in Patients With Refractory Glaucoma. Unknown status NCT01314170 Phase 3
9 Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma Unknown status NCT01128699 Phase 3 Subconjunctival Avastin
10 Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients Completed NCT02396316 Phase 3 Aflibercept (Eylea, BAY 86-5321);Sham Injection
11 Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis Completed NCT02641457 Phase 3 Aflibercept;Ranibizumab
12 Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion Completed NCT02033031 Phase 3 Lucentis intravitreal injection;Avastin intravitreal injection
13 Bevacizumab for Central Retinal Vein Occlusion Study Completed NCT00906685 Phase 3 bevacizumab;Sham bevacizumab injection
14 An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Completed NCT01908816 Phase 3 ranibizumab
15 Oculusgen (Ologen) Glaucoma MMC Control in Estonia Completed NCT00524758 Phase 3 MMC in Trabeculectomy
16 Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery? Completed NCT00853905 Phase 2, Phase 3 Triesence;balanced salt solution BSS
17 Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied Recruiting NCT03639675 Phase 3 Aflibercept (EYLEA, BAY86-5321);Topical IOP-lowering drugs
18 Anti-VEGF Treatment for Prevention of PDR/DME Active, not recruiting NCT02634333 Phase 3 Prompt aflibercept;Deferred aflibercept
19 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3 Aflibercept Injection;False injection
20 Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG Not yet recruiting NCT02947867 Phase 2, Phase 3 aganirsen
21 A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy Withdrawn NCT01589718 Phase 3 Macugen;Sham
22 Phase II Evaluating Endoresection of the Tumor Scar or Transpupillary Thermotherapy When Endoresection is Not Feasible After Proton Beam Therapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Unknown status NCT02874040 Phase 2
23 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy Unknown status NCT03006081 Phase 2 Intravitreal Aflibercept injection
24 Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment. Unknown status NCT02957760 Phase 2 Hydroxycarbamid
25 Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma Completed NCT01051583 Phase 2
26 Analysis of Aqueous and Vitreous Humor Recruiting NCT02067013 Phase 2 Ranibizumab
27 Ahmed Glaucoma Valve Surgery With Mitomycin-C Active, not recruiting NCT02805257 Phase 2 Mitomycin-C
28 Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. Active, not recruiting NCT02222610 Phase 2 0.5 mg ranibizumab
29 Lucentis for New Onset Neovascular Glaucoma Withdrawn NCT00727038 Phase 1, Phase 2 Ranibizumab (Lucentis)
30 Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion Completed NCT00406471 Phase 1 Ranibizumab (Lucentis)
31 A Pilot Study for the Treatment of Iris Neovascularization With Macugen Completed NCT00295828 Phase 1
32 Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma Unknown status NCT02260219 Not Applicable
33 Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection Unknown status NCT00491712 Not Applicable
34 Triamcinolone for Ahmed Glaucoma Valve Unknown status NCT02653963 Not Applicable Adjunctival Triamcinolone
35 Prevalence of Glaucoma in the Israeli Arab Population Unknown status NCT01546740
36 Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma Completed NCT01370135 Not Applicable 0.5mg intraocular Ranibizumab (Lucentis)
37 The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma Completed NCT03154892 Not Applicable
38 Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma Completed NCT01711879 Not Applicable Aflibercept
39 Intravitreal Bevacizumab for Neovascular Glaucoma Completed NCT00384631 Not Applicable Avastin
40 Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy Completed NCT01758757 Not Applicable
41 Comparison of Subconjuctival Versus Topical Bevacizumab as Adjunct Therapy to Trabeculectomy Completed NCT01425112 Not Applicable
42 Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion Completed NCT02645747 Aflibercept (Eylea, BAY86-5321)
43 Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy Completed NCT01307072
44 the Pops-titration Versus the Slow-coagulation Cyclophotocoagulation in Treatment of Refractory Glaucoma Completed NCT01774227 Not Applicable
45 Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT Recruiting NCT03648814 Not Applicable
46 Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and PEX - a Pilot Study Recruiting NCT02865473 Not Applicable Pilocarpine
47 Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube Terminated NCT01301378 Not Applicable
48 Radial Optic Neurotomy in Central Retinal Vein Occlusion : a Randomized Trial Terminated NCT00379223 Not Applicable
49 Effects of Travoprost on Neovascular Glaucoma Withdrawn NCT00441181 Not Applicable Travoprost

Search NIH Clinical Center for Neovascular Glaucoma

Cochrane evidence based reviews: glaucoma, neovascular

Genetic Tests for Neovascular Glaucoma

Anatomical Context for Neovascular Glaucoma

MalaCards organs/tissues related to Neovascular Glaucoma:

41
Eye, Endothelial, Testes, Lung, Retina, B Cells, Placenta

Publications for Neovascular Glaucoma

Articles related to Neovascular Glaucoma:

(show top 50) (show all 448)
# Title Authors Year
1
Intravitreal bevacizumab as therapy for refractory neovascular glaucoma secondary to iris metastasis of breast carcinoma. ( 29468218 )
2018
2
Iris Thickness and Severity of Neovascular Glaucoma Determined Using Swept-Source Anterior-segment Optical Coherence Tomography. ( 29485476 )
2018
3
Comparison of the safety and efficacy of triple sequential therapy and transscleral cyclophotocoagulation for neovascular glaucoma in the angle-closure stage. ( 29728640 )
2018
4
Comparison of polypropylene and silicone AhmedAr glaucoma valves in the treatment of neovascular glaucoma: A 2-year follow-up. ( 29521039 )
2018
5
Puerarin regulates neovascular glaucoma through pigment epitheliuma89derived growth factora89induced NFa89I_B signaling pathway. ( 29620183 )
2018
6
Assessing the role of ranibizumab in improving the outcome of glaucoma filtering surgery and neovascular glaucoma. ( 29781319 )
2018
7
Rapidly progressive neovascular glaucoma following coronary artery bypass graft surgery in a patient with type 1 diabetes mellitus: a case report. ( 29429414 )
2018
8
RAPIDLY PROGRESSIVE NEOVASCULAR GLAUCOMA FROM CYTOMEGALOVIRUS RETINITIS IN A NON-HUMAN IMMUNODEFICIENCY VIRUS PATIENT. ( 29533389 )
2018
9
Left acute neovascular glaucoma after right carotid endarterectomy. ( 29942895 )
2018
10
An atypical case of neurosarcoidosis presenting with neovascular glaucoma. ( 29671151 )
2018
11
Topical Corticosteroid-Resolved Rubeosis Iridis with Neovascular Glaucoma Caused by Noninfectious Granulomatous Uveitis. ( 29681844 )
2018
12
Pars plana insertion of glaucoma shunt in eyes with refractory neovascular glaucoma: Case report. ( 29879052 )
2018
13
Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy. ( 29116399 )
2018
14
Systemic diffuse large B-cell lymphoma masquerading as neovascular glaucoma. ( 29380792 )
2018
15
Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients: A PRISMA-compliant network meta-analysis. ( 29620670 )
2018
16
Clinical Efficacy and Safety of the EX-PRESS Filtration Device in Patients with Advanced Neovascular Glaucoma and Proliferative Diabetic Retinopathy. ( 29643784 )
2018
17
Neovascular glaucoma: Handling in the future. ( 30038883 )
2018
18
A Case of Refractory Neovascular Glaucoma Treated With a XEN 45 Implant. ( 30059408 )
2018
19
Safety of antivascular endothelial growth factor administration in the ocular anterior segment in pterygium and neovascular glaucoma treatment: Systematic review and meta-analysis. ( 30142821 )
2018
20
Prediction of Surgical Outcome After Trabeculectomy for Neovascular Glaucoma With Anterior-segment Optical Coherence Tomography. ( 30188465 )
2018
21
High interleukin-8 level in aqueous humor is associated with poor prognosis in eyes with open angle glaucoma and neovascular glaucoma. ( 30266980 )
2018
22
A Case Report of Intravitreal Bevacizumab for Iris Metastasis of Small Cell Lung Carcinoma with Neovascular Glaucoma. ( 30283326 )
2018
23
Iris Morphological Features in Patients with 360° Angle-Closure Neovascular Glaucoma: An Anterior Segment Optical Coherence Tomography Study. ( 30483110 )
2018
24
Prediction of Surgical Outcome After Trabeculectomy for Neovascular Glaucoma With Anterior-segment Optical Coherence Tomography: A Methodological Issues. ( 30531190 )
2018
25
Risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy. ( 30532517 )
2018
26
Changing epidemiology of neovascular glaucoma from 2002 to 2012 at King Khaled Eye Specialist Hospital, Saudi Arabia. ( 29044062 )
2017
27
Efficacy and safety of intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy compared with Ahmed glaucoma valve implantation in neovascular glaucoma. ( 28393031 )
2017
28
Long-Term Outcome of Intravitreal Bevacizumab Followed by Ahmed Valve Implantation in the Management of Neovascular Glaucoma. ( 28992424 )
2017
29
The efficacy of Alahmady ring implantation in the management of neovascular glaucoma. ( 28356708 )
2017
30
Efficacy and Safety of Intracameral Bevacizumab for Treatment of Neovascular Glaucoma. ( 29022296 )
2017
31
Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy. ( 28272234 )
2017
32
Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience. ( 28848323 )
2017
33
Central retinal artery occlusion without underlying chronic ocular ischemic syndrome may lead to neovascular glaucoma. ( 29055729 )
2017
34
Management of neovascular glaucoma with intravitreal ranibizumab, panretinal photocoagulation, and subsequent 5-fluorouracil augmented trabeculectomy: A case report. ( 28640115 )
2017
35
Clinical efficacy analysis of Ahmed glaucoma valve implantation in neovascular glaucoma and influencing factors: A STROBE-compliant article. ( 29049253 )
2017
36
Chronic Retinal Necrosis Severely Complicated by Neovascular Glaucoma: A Case Report. ( 29282399 )
2017
37
Intracameral air injection during Ahmed glaucoma valve implantation in neovascular glaucoma for the prevention of tube obstruction with blood clot: Case Report. ( 29390305 )
2017
38
Circumpapillary retinal nerve fiber layer thickness, anterior lamina cribrosa depth, and lamina cribrosa thickness in neovascular glaucoma secondary to proliferative diabetic retinopathy: a cross-sectional study. ( 28446148 )
2017
39
Short-term outcomes after EX-PRESS implantation versus trabeculectomy alone in patients with neovascular glaucoma. ( 29276376 )
2017
40
Neovascular Glaucoma: A Retrospective Review from a Tertiary Eye Care Center in Mexico. ( 28924338 )
2017
41
Ahmed valves vs trabeculectomy combined with pans plana vitrectomy for neovascular glaucoma with vitreous hemorrhage. ( 28430329 )
2017
42
Neovascular glaucoma after proton beam therapy of choroidal melanoma: incidence and risk factors. ( 28721444 )
2017
43
Surgical treatment of neovascular glaucoma with Ex-PRESS glaucoma shunt: Case report. ( 28858093 )
2017
44
Effect of Preoperative Intravitreal Bevacizumab on the Surgical Outcome of Neovascular Glaucoma at Different Stages. ( 28713590 )
2017
45
A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol for a randomised controlled trial. ( 28302155 )
2017
46
Association of Neovascular Glaucoma with Risk of Stroke: A Population-Based Cohort Study. ( 28928981 )
2017
47
Clinical Features of Ocular Ischemic Syndrome and Risk Factors for Neovascular Glaucoma. ( 28682017 )
2017
48
Choroidal hypoperfusion: an indicator of low tension neovascular glaucoma. ( 29256166 )
2017
49
Paradoxical development of neovascular glaucoma following carotid angioplasty and stenting. ( 27341857 )
2016
50
Management of intraocular pressure elevation during hemodialysis of neovascular glaucoma: a case report. ( 26944556 )
2016

Variations for Neovascular Glaucoma

Expression for Neovascular Glaucoma

Search GEO for disease gene expression data for Neovascular Glaucoma.

Pathways for Neovascular Glaucoma

Pathways related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.1 PGF TGFB2 VEGFA
2 10.97 TGFB2 VEGFA
3 10.65 TGFB2 VEGFA
4
Show member pathways
9.83 PGF VEGFA

GO Terms for Neovascular Glaucoma

Cellular components related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.62 TGFB2 VEGFA

Biological processes related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.71 PGF TGFB2 VEGFA
2 angiogenesis GO:0001525 9.58 PGF TGFB2 VEGFA
3 positive regulation of endothelial cell proliferation GO:0001938 9.52 PGF VEGFA
4 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.51 PGF VEGFA
5 heart morphogenesis GO:0003007 9.49 TGFB2 VEGFA
6 cellular response to hormone stimulus GO:0032870 9.48 PGF UCP2
7 positive chemotaxis GO:0050918 9.46 PGF VEGFA
8 cell death GO:0008219 9.43 OPTN TGFB2
9 sprouting angiogenesis GO:0002040 9.37 PGF VEGFA
10 vascular endothelial growth factor signaling pathway GO:0038084 9.32 PGF VEGFA
11 induction of positive chemotaxis GO:0050930 9.26 PGF VEGFA
12 positive regulation of mast cell chemotaxis GO:0060754 9.16 PGF VEGFA
13 positive regulation of cell division GO:0051781 9.13 PGF TGFB2 VEGFA
14 response to hypoxia GO:0001666 8.92 PGF TGFB2 UCP2 VEGFA

Molecular functions related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemoattractant activity GO:0042056 9.16 PGF VEGFA
2 growth factor activity GO:0008083 9.13 PGF TGFB2 VEGFA
3 vascular endothelial growth factor receptor 3 binding GO:0043185 8.62 PGF VEGFA

Sources for Neovascular Glaucoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....